- $904.42m
- $616.33m
- $76.99m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.23 | ||
| Price to Tang. Book | 3.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.71% | ||
| Return on Equity | -66.09% | ||
| Operating Margin | -227.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.25 | 1.39 | 0.6 | 0.24 | 76.99 | 222.33 | 347.97 | 178.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Directors
- John Scarlett CHM (70)
- Olivia Bloom CFO (52)
- Andrew Grethlein COO (56)
- Stephen Rosenfield EVP (70)
- Anil Kapur EVP (51)
- Melissa Kelly Behrs EVP (57)
- Edward Koval EVP
- Aleksandra Rizo EVP (46)
- Karin Eastham LED (71)
- Dawn Bir IND (50)
- V. Bryan Lawlis IND (69)
- Susan Molineaux IND (67)
- Elizabeth O'Farrell IND (56)
- Robert Spiegel IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 28th, 1990
- Public Since
- July 31st, 1996
- No. of Shareholders
- 439
- No. of Employees
- 229
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 636,912,845
- Address
- 919 East Hillsdale Boulevard, Suite 250, FOSTER CITY, 94404
- Web
- https://www.geron.com/
- Phone
- +1 6504737700
- Auditors
- Ernst & Young LLP
Upcoming Events for GERN
Q1 2025 Geron Corp Earnings Release
Geron Corp Annual Shareholders Meeting
Geron Corp Annual Shareholders Meeting
Q2 2025 Geron Corp Earnings Release
Similar to GERN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Geron share price?
As of Today at 20:48 UTC, shares in Geron are trading at $1.42. This share price information is delayed by 15 minutes.
How has the Geron share price performed this year?
Shares in Geron last closed at $1.42 and the price had moved by -60.11% over the past 365 days. In terms of relative price strength the Geron share price has underperformed the S&P500 Index by -63.18% over the past year.
What are the analyst and broker recommendations for Geron?
The overall consensus recommendation for Geron is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Geron dividend yield?
Geron does not currently pay a dividend.
Does Geron pay a dividend?
Geron does not currently pay a dividend.
When does Geron next pay dividends?
Geron does not currently pay a dividend.
How do I buy Geron shares?
To buy shares in Geron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Geron?
As of the previous close price of $1.42, shares in Geron had a market capitalisation of $904.42m.
Where are Geron shares listed?
Here are the trading details for Geron:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GERN
What kind of share is Geron?
Based on an overall assessment of its quality, value and momentum Geron is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Geron share price forecast for 2025?
The analyst consensus target price for shares in Geron is $4.13. That is 190.85% above the last closing price of $1.42.
Analysts covering Geron currently have a consensus Earnings Per Share (EPS) forecast of -$0.12 for the next financial year.
Find out moreWhat is the trend in the Geron share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Geron. Over the past six months, its share price has underperformed the S&P500 Index by -63.14%.
As of the last closing price of $1.42, shares in Geron were trading -58.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Geron PE Ratio?
The Geron PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Geron?
Geron's management team is headed by:
- John Scarlett - CHM
- Olivia Bloom - CFO
- Andrew Grethlein - COO
- Stephen Rosenfield - EVP
- Anil Kapur - EVP
- Melissa Kelly Behrs - EVP
- Edward Koval - EVP
- Aleksandra Rizo - EVP
- Karin Eastham - LED
- Dawn Bir - IND
- V. Bryan Lawlis - IND
- Susan Molineaux - IND
- Elizabeth O'Farrell - IND
- Robert Spiegel - IND